Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

AstraZeneca PLC ADR

AZN
Current price
65.09 USD +0.71 USD (+1.10%)
Last closed 64.27 USD
Sector Healthcare
Industry Drug Manufacturers - General
Exchange NASDAQ
Capitalization 201 380 347 904 USD
Yield for 12 month -5.46 %
1Y
3Y
5Y
10Y
15Y
AZN
21.11.2021 - 28.11.2021

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, andcommercialization of prescription medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. Its marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; and Personalis, Inc, as well as research collaboration with Sernova Corp. to evaluate novel potential therapeutic cell applications; and collaboration with Cholesgen (Shanghai) Co.Ltd. to advance research and development in hypercholesterolemia and related metabolic diseases, as well as a collaboration with BioCity Biopharma to evaluate a monoclonal antibody for the treatment of advanced hepatocellular carcinoma and a collaboration agreement with Cellectis. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom. Address: 1 Francis Crick Avenue, Cambridge, United Kingdom, CB2 0AA

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

81.11 USD

P/E ratio

33.678

Dividend Yield

2.23 %

Current Year

+44 994 000 000 USD

Last Year

+44 351 000 000 USD

Current Quarter

+11 492 000 000 USD

Last Quarter

+11 416 000 000 USD

Current Year

+36 134 000 000 USD

Last Year

+31 960 000 000 USD

Current Quarter

+9 397 000 000 USD

Last Quarter

+9 456 000 000 USD

Key Figures AZN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA 13 656 999 936 USD
Operating Margin TTM 11.58 %
PE Ratio 33.678
Return On Assets TTM 5.51 %
PEG Ratio 0.4688
Return On Equity TTM 15.64 %
Wall Street Target Price 81.11 USD
Revenue TTM 45 810 999 296 USD
Book Value 25.27 USD
Revenue Per Share TTM 2.45 USD
Dividend Share 2.9 USD
Quarterly Revenue Growth YOY 7.3 %
Dividend Yield 2.23 %
Gross Profit TTM 35 732 000 000 USD
Earnings Share 1.91 USD
Diluted Eps TTM 1.91 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY 6.8 %
Profit Margin 13 %

Dividend Analytics AZN

Dividend growth over 5 years

4 %

Continuous growth

Payout Ratio 5 years average

834 %

Dividend History AZN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate 1.45
Ex Dividend Date 22.02.2024
Forward Annual Dividend Yield 2.23 %
Last Split Factor 2:1
Payout Ratio 66.9 %
Last Split Date 27.07.2015
Dividend Date 25.03.2024

Stock Valuation AZN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 33.678
Forward PE 15.3846
Enterprise Value Revenue 4.8427
Price Sales TTM 4.3959
Enterprise Value EBITDA 16.5288
Price Book MRQ 5.1524

Financials AZN

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators AZN

For 52 weeks

60.47 USD 76.06 USD
50 Day MA 66.11 USD
Shares Short Prior Month 5 806 279
200 Day MA 67.98 USD
Short Ratio 0.72
Shares Short 4 098 637
Short Percent 0.27 %

Dynamics of changes in the value of assets

Stocks


MSFT

MSFT

402.79 USD Microsoft Corporation -0.45 (-0.11%)
Detailed analytics

ETF funds


S

SX7EEX

11.59 EUR iShares EURO STOXX Banks 30-15 UCITS ETF (DE) 0 (0%)
Detailed analytics

Metals


Gold

2031.07 USD Gold +9.2 (+0.46%)
Detailed analytics